Gaudium IVF and Women Health Limited has scheduled an analyst and institutional investor meet for June 12, 2026, to engage with the investment community. The virtual meeting, organized by Choice Broking, will provide a platform for discussions based on publicly available information. No unpublished price sensitive information will be shared during the session, and no presentation is planned.

The meeting is scheduled to take place from 11.00 AM to 12:00 PM. The event is part of the company's ongoing investor relations activities conducted under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Schedule of Meeting

The company noted that the schedule is subject to change due to exigencies. Further details and updates regarding the meeting will be available on the company's website.

Gaudium IVF and Women Health Limited reported a 28% increase in consolidated net profit for the financial year ended March 31, 2026, reaching ₹24.48 crore, compared to ₹19.17 crore in the previous year. Revenue from operations for FY26 grew 48% to ₹104.35 crore from ₹70.72 crore in FY25. The company's board approved the audited standalone and consolidated financial results on May 28, 2026.

For the quarter ended March 31, 2026, the company reported a consolidated net profit of ₹8.36 crore, an increase of 29% from ₹6.45 crore in the corresponding quarter of the previous year. Revenue for the quarter stood at ₹30.35 crore, with EBITDA rising 40% year-on-year to ₹12.17 crore. The statutory auditors, S K G N & Associates LLP, issued an unmodified opinion on the financial results.

Consolidated Financial Performance

The company achieved an EBITDA margin of 40.10% in Q4FY26, compared to 32.39% in the prior year. For the full year, the EBITDA margin was 36.13%. Profit After Tax (PAT) from continuing operations for FY26 was ₹24.48 crore, with a PAT margin of 23.47%.

Key Ratios and Cash Flows

The company's Return on Equity (RoE) average for FY26 was 24.66%, while Return on Capital Employed (RoCE) average stood at 34.80%. The Debt/Equity ratio improved to 0.16, reflecting the impact of the ₹90 crore fresh equity infusion through the IPO listed on February 27, 2026.

Cash flow from operating activities for FY26 was ₹724.72 lakh, while cash used in investing activities was ₹8,765.41 lakh. Net cash and cash equivalents increased by ₹157.07 lakh to close at ₹878.57 lakh.

Operational Highlights and Future Outlook

Gaudium IVF maintained a network of 7 hubs and 28 spokes in FY26, delivering a clinical pregnancy success rate of 58% on the first IVF attempt. In April 2026, the company became the first IVF chain in India to integrate AI-led embryology into routine clinical practice through a partnership with UK-headquartered IVF 2.0, deploying the SiD and ERICA platforms.

Dr. Manika Khanna, Chairperson and Managing Director, attributed the growth to higher patient volume at mature hubs and a high clinical success rate. She outlined the expansion strategy, noting that of the 19 new IVF hubs planned under the IPO use-of-proceeds, 3 are expected to be operational soon. The company plans to take the total hub count to 10 in FY27, followed by 8 in FY28 and 1 in FY29, expanding deeper into Tier-II markets.

Regulatory Disclosure

Pursuant to Regulation 30 and Regulation 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, the company has informed that the audio recording of the earnings call on the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, is available. The recording, held on Friday, May 29, 2026, has been uploaded to the company's website at https://www.gaudiumivfcentre.com/audio-player/q4-fy26 .